Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit turns positive

Q3 FY2026 gross profit was $0, compared with -$19.86M a year earlier. Trailing-twelve-month gross profit was -$108K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$27K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
-$525K-101.2% YoY
LTMSep 2026
-$108K+99.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-101.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(525K) USD
Year-over-year change
-101.2%

Gross Profit vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +99.7% is the highest of 6, against a peer median of -80.3%.
AMLX Competitors
Gross Profit for AMLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$942.72M USD-1.3%+17.4%98.2%
PRTAProthena Corporation plcLTM Mar 2026$27.14M USD-80.3%-51.9%46.8%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026-$108K USD+99.7%——
CLNNClene Inc.LTM Mar 2026-$244K USD-188.4%-29.4%182.1%
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.2M USD——61.0%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$77.55M USD+67.5%——
Peer median (excluding AMLX) —-80.3%-16.3%98.2%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue022.23M380.79M87.37M0
Cost of Revenue02.99M25.44M42.16M525K
Gross Profit019.24M355.35M45.22M(525K)
Gross Margin—86.5%93.3%51.8%—
Research & Development44.04M93.45M128.19M104.08M90.4M
Selling, General & Admin38.93M127.13M188.36M114.33M62.89M
Operating Expenses82.69M220.58M316.54M359.95M152.77M
Depreciation & Amortization52K487K1.09M904K525K
EBITDA(87.88M)(197.11M)55.39M(290.98M)(144.16M)
EBITDA Margin—-886.7%14.5%-333.0%—
Operating Income(82.69M)(201.34M)38.8M(314.73M)(153.29M)
Operating Margin—-905.7%10.2%-360.2%—
Interest Income36K4.29M16.16M13.81M9.3M
Interest Expense00000
Other Income / Expenses(5.24M)3.74M15.5M12.6M8.6M
Income Before Tax(87.93M)(197.6M)54.3M(302.14M)(144.69M)
Pre-Tax Margin—-888.9%14.3%-345.8%—
Income Tax Expense0774K5.03M(393K)46K
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Net Margin—-892.4%12.9%-345.4%—
EPS (Basic)(1.52)(2.98)0.73(4.43)(1.53)
EPS (Diluted)(1.52)(2.98)0.70(4.43)(1.53)
Weighted Avg Shares57.86M66.51M67.23M68.14M94.57M
Weighted Avg Shares (Diluted)57.86M66.51M69.99M68.14M94.57M

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.